[Evaluation of the efficiency of gemfibrozil in treating hyperlipidemia type IIb and IV].
Analysis of the efficacy and tolerability of gemfibrozil (Gevilon-Parke Davis) was performed including 29 patients aged 19-69 years with primary hyperlipoproteinemia (HLP) type IIb-16 persons, IV-13 persons. All patients got dietary recommendations and received gemfibrozil 450-900 mg/day for 3 months. In both types of HLP a significant reduction of serum cholesterol (TCh)--15.5% triglycerides (TG)--32.1% VLDL-Ch--34.9% and VLDL-TG concentration--36.6% was observed as well as an increase of HDL3 fraction-16.3%. The greatest reduction of serum TCh concentration and VLDL-Ch were observed in type IIb, while that of TG and VLDL-TG in type IV HLP. The best therapeutic effect was obtained during the first month of treatment. The percent of TCh, TG, VLDL-Ch, VLDL-TG reduction correlated with their initial level. Tolerability of gemfibrozil was very good. Only in 2 patients transient abdominal pain was observed.
Polakowska
M
M
Zakładu Epidemiologii i Prewencji Chorób Układu Krazenia Instytutu Kardiologii, Warszawie.
Broda
G
G
Rywik
S
S
Piotrowski
W
W
Bednarska
M
M
Kuźmińska
A
A
Pytlak
A
A
Chotkowska
E
E
D000293:Adolescent; D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D005260:Female; D015248:Gemfibrozil / Q000627:therapeutic use*; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy*; D006953:Hyperlipoproteinemia Type IV / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D015243:Cholesterol, VLDL; D014280:Triglycerides; D002784:Cholesterol; D015248:Gemfibrozil
Ocena skuteczności gemfibrozilu w leczeniu hiperlipidemii typu IIb i IV.